Namibia - English - Namibia Medicines Regulatory Council

aurobindo pharma (pty) ltd - cefalexin monohydrate - tablet - each tablet contains cefalexin monohydrate equivalent to cefalexin 250,0 mg

Namibia - English - Namibia Medicines Regulatory Council

aurobindo pharma (pty) ltd - cefalexin monohydrate - tablet - each tablet contains cefalexin monohydrate equivalent to cefalexin 500,0 mg

Namibia - English - Namibia Medicines Regulatory Council

aurobindo pharma (pty) ltd - cefalexin monohydrate - tablet - each tablet contains cefalexin monohydrate equivalent to cefalexin 1000,0 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - cefalexin monohydrate -

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefalexin monohydrate 262.9mg equivalent to cephalexin 250 mg;   - capsule - 250 mg - active: cefalexin monohydrate 262.9mg equivalent to cephalexin 250 mg   excipient: gelatin   magnesium stearate microcrystalline cellulose titanium dioxide   water  

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - cefalexin monohydrate, quantity: 275 mg (equivalent: cefalexin, qty 250 mg) - capsule, hard - excipient ingredients: sunset yellow fcf; lactose monohydrate; iron oxide yellow; titanium dioxide; magnesium stearate; gelatin; brilliant blue fcf; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following infections when caused by susceptible strains of the designated micro-organisms. respiratory tract infections - caused by s. pneumoniae and group a b-haemolytic streptococci. (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis - caused by streptococci, s. pneumoniae and s aureus (methicillin sensitive only). otitis media - due to s. pneumoniae, staphylococci; skin and skin structure infections - caused by staphylococci and/or streptococci; genitourinary tract infections, including acute prostatitis - caused by e. coli, p. mirabilis and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions. note:- appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - cefalexin monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - cefalexin -

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - cefalexin -

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - cefalexin, quantity: 250 mg - capsule - excipient ingredients: microcrystalline cellulose; patent blue v; sunset yellow fcf; gelatin; quinoline yellow; purified water; titanium dioxide; sodium lauryl sulfate; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin max capsule is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin capsule in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin sensitive only). otitis media. due to s. pneumoniae, staphylococci. skin and soft tissue infections. caused by staphylococci and/or streptococci. genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis and klebsiella sp. the effectiveness of cephalexin max capsule in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin max capsule is not indicated in these conditions. note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin max capsule. renal function studies should be performed when indicated.